Clinical Trial Update: A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

View source ↗

Summary

This document outlines a clinical trial update describing persistence with ozanimod treatment in relapsing-remitting multiple sclerosis (RRMS) participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Relapsing-remitting Multiple Sclerosis (RRMS) | Status: ACTIVE_NOT_RECRUITING